Clinical improvement and normalized Th1 cytokine profile in early and long-term interferon-alpha treatment in a suspected case of hyper-IgE syndrome.
We are reporting on a 7-months-old boy with suspected hyper-IgE syndrome, presenting with a therapy resistant severe eczema and an overall reduction of in vitro cytokine production. Interferon-alpha (IFN-alpha) treatment resulted in a marked and stable clinical improvement and normalization of in vitro T-cell cytokine production, indicating a valid therapeutic potential of IFN-alpha as immunomodulating drug.
Benninghoff
Ulrike
U
Pediatric Clinical Research Unit, San Raffaele Telethon Institute for Gene Therapy (HSR-TIGET), Milan, Italy.
Cattaneo
Federica
F
Aiuti
Alessandro
A
Flores-D'Arcais
Alberto
A
Gelmetti
Carlo
C
Viscardi
Matteo
M
Callegaro
Luciano
L
Mirolo
Massimiliano
M
Ambrosi
Alessandro
A
Roncarolo
Maria Grazia
MG
Bacchetta
Rosa
R
D002648:Child; D016207:Cytokines / Q000032:analysis* / Q000276:immunology; D004485:Eczema / Q000188:drug therapy* / Q000276:immunology; D004802:Eosinophilia / Q000276:immunology; D006801:Humans; D007073:Immunoglobulin E / Q000097:blood*; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000627:therapeutic use*; D007589:Job Syndrome / Q000188:drug therapy* / Q000276:immunology; D008297:Male; D011994:Recombinant Proteins; D018417:Th1 Cells / Q000276:immunology / Q000378:metabolism; D018418:Th2 Cells / Q000276:immunology / Q000378:metabolism
D016207:Cytokines; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D007073:Immunoglobulin E